Anavex Life Sciences Corp (AVXL)

[falconer66a]

Lunchtime Talk at the FDA

So, perhaps the FDA is now going to give us Act 2, and rectify their recent ridiculous AD drug approvals ... accelerated approvals, no less!

On this matter one must consider what “the FDA” actually is, or what “the FDA” might know about Anavex.

Of course, it must be presumed that “the FDA” in this context must be the actual FDA officials who approve new drugs. The Food and Drug Administration must have thousands of employees. But only a slight few actually officially vote to approve or disapprove of a new drug that has a New Drug Application (NDA) submitted to the agency.

Whadya think? Do the FDA officials who approve new drugs carefully and deliberately refrain from trying to learn any common or online information about new drugs that might be coming before them? Or, being medical and scientific research experts, better than most who post on this message board, might certain FDA officials closely monitor and consider the information appearing for drugs like blarcamesine or Anavex 3-71?

If it’s the later (most likely), things Anavex must be looking evermore positive.

At lunchtime at the FDA, are there any conversations, asking, “Say, did you see the latest on that blarcamesine drug? Sure seems to beat the -mabs we just approved for Alzheimer’s.”